In 2001, the breakthrough discovery of the involvement of the Wnt signalling pathway on the regulation of bone remodelling was made possible by the study of rare conditions such as osteoporosis-pseudoglioma syndrome (OPPG) due to LRP5 mutations (11) and sclerosteosis due to SOST defects (12,13). This evidence concerns the gene SOST and sclerosteosis.